Telegram RegisterThe public register of Telegram

Channel

(사)바이오헬스케어협회

@bioha1228

On this record: Growth · Engagement · Reactions · Posts · Citations · Cite this entry

2,750subscribers

+98 since we began measuring on 7 August 2026

Risers and fallers across the register · movement among entries of 1,000–3,162.

Register entry

Telegram ID-1001788561514
TypeChannel
Username@bioha1228
CreatedBetween 1 December 2021 and 30 April 2023— estimated from Telegram’s id allocation, not measured. How this range is calculated.
First recorded7 August 2026
Last confirmed live14 August 2026
Measurements held4
Confirmed unchanged1 time, most recently 14 August 2026
On Telegramt.me/bioha1228

Growth

2,6512,7502,700.57 August 2026 — 2,652 subscribers8 August 2026 — 2,651 subscribers10 August 2026 — 2,655 subscribers14 August 2026 — 2,750 subscribers7 August 202614 August 2026
4 measurements spanning 7 days, net +98. Dots are measurements; the straight line between them is drawn to join them, not to claim we know the path taken in between — snapshots are recorded only when a count changes, so gaps mean “no change observed”, never “interpolated”. The vertical axis spans 2,636–2,765 and does not start at zero.
Measurement log — every subscribers count we have recorded
Measured (UTC)SubscribersChange
14 Aug 2026, 08:362,750+95
10 Aug 2026, 23:362,655+4
8 Aug 2026, 08:432,651-1
7 Aug 2026, 09:022,652first reading

Engagement

20 posts held, back to 6 August 2026the reader has not yet reached the start of this channel’s public history, so older posts may sit further back, unread. Read across 2 pagesof Telegram’s post history, 20 posts per page.

ERR · 30 days
5.32%
avg views ÷ 2,750 subscribers
Avg views / post
146
20 posts measured
Reaction rate
0.301%
reactions ÷ views · ER floor
Posts in window
20
of 20 held

ERR is average views per post over the last 30 days divided by subscribers, the definition TGStat uses, so this figure is comparable with the one you will see elsewhere. It falls structurally as a channel grows: a high ERR on a small channel and a low one on a large channel describe reach mathematics, not quality. We publish the figure and the sample it came from and pass no verdict on it.

ER is defined industry-wide as (forwards + reactions + comments) ÷ views— note the denominator is views, not subscribers. Telegram’s public web preview carries views and reactions but not forward or comment counts, so the reaction rate above is the reactions term only and is therefore a floor: the true ER for this channel is higher by an amount we have not measured and will not estimate. It is computed over the 2 of 20 measured posts that carry a reaction reading, and over those same posts' views.

What these figures were computed from
WindowRolling 30 days · latest post in window 7 August 2026
Posts held20 (6 August 20267 August 2026)
Views total2,926
Reactions total1
Forwards / commentsnot exposed by the public surface — not measured, not estimated
Readings taken7 Aug 2026, 16:18 UTC

Views are a single reading per post, taken at the time above. A post published in the last day or two is still accumulating views, which pulls the 30-day average down slightly. That is a property of the standard definition rather than a fault in it, so we keep the definition rather than “correcting” the number into something nobody can reproduce.

Precision. Telegram publishes view counts on its public widget in short form — 8.12K, 3.7M — so any reading at or above 1,000 reaches us rounded to three significant figures, and only counts below 1,000 are exact. Averages and rates derived from them are shown to the same precision rather than to the unit: a figure like 3,701,250 would assert digits nobody measured.

Reaction counts are published per emoji and rounded the same way, so a total below 1,000 is exact and a larger one is a sum that may carry a rounded component from each emoji above 1,000. Because it is a sum, it does not look rounded — read a large reaction total as three significant figures per contributing emoji rather than as the figure it prints.

Reaction mix

1 reaction across 1 post, in 1 kind.

Every reaction kind recorded on the sample, most used first
ReactionCountShareShare, drawn
1100.0%

No sentiment is inferred, and none should be read in. This table is ordered by count and by nothing else. Emoji do not carry stable meaning across languages or communities — 🙏 is thanks in one channel and mourning in another — so we publish which ones were pressed and how often, and pass no judgement on what an audience meant by them.

Precision. Telegram publishes reaction counts per emoji and short-forms each one — 4.34K, 1.2M — so any single kind at or above 1,000 reaches us at three significant figures, and only counts below 1,000 are exact. The shares above are ratios of those figures and carry the same error. This is also why the total here can differ slightly from a reaction total printed elsewhere on the page: both are sums of the same rounded parts, taken over samples with different edges.

Coverage. Reactions were read on 2 of the 20 sampled posts in this sample. Summed by Telegram’s own count on each post — not by adding up the per-emoji breakdown above — those same posts carry 1reactions in total: the kind of figure the paragraph above means by “a reaction total printed elsewhere on the page”.

Measured over the 20 most recent posts we hold, published 6 August 2026 to 7 August 2026, using the newest reading held for each. Telegram Stars are excluded: they are a payment, not a reaction, and they have their own section.

Recent posts

7 Aug 2026, 09:10 UTC75 viewsread 7 August 2026
Forwarded from @alteogenIR

안녕하세요. 세계 최대 자산운용사 BlackRock이 알테오젠 주식 5.03%를 보유하고 있다고 조금 전 공시를 통해 밝혔습니다. 단순투자목적으로 취득했고, 자세한 내용은 하단 공시를 통해 확인해주시기 바랍니다. - 공시 링크: https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20260807000762

7 Aug 2026, 08:51 UTC126 viewsread 7 August 2026
Forwarded from @pharmbiohana

곤자가님이 정리 잘 해주심❤️ https://www.moneytoring.ai/post/UG9zdFR5cGU6NTYzMg%3D%3D

7 Aug 2026, 08:31 UTC150 viewsread 7 August 2026

2026.08.07 17:30:39 기업명: 알테오젠(시가총액: 16조 3,438억) A196170 보고서명: 주식등의대량보유상황보고서(약식) 대표보고 : 블랙록 펀드 어드바이저스/미국 보유목적 : 단순투자 보고전 : -% 보고후 : 5.03% 보고사유 : - 단순투자목적으로 장내에서 발행회사의 주식 매수 * BlackRock(Netherlands) B.V. 2026-07-30/신규보고(+)/보통주/ 13,438주/5% 미만/주) * BlackRock(Singapore) Limited 2026-07-30/신규보고(+)/보통주/ 3,880주/5% 미만/주) * BlackRockAdvisors (UK)Limited 2026-07-30/신규보고(+)/보통주/ 431,361주/5% 미만/주) 2026-07-31/장내매수(+)/보통주/ 399

7 Aug 2026, 08:17 UTC90 viewsread 7 August 2026
Forwarded from @growthbio

🧬 펩트론 주요 문의(FAQ)에 대한 답변 (2) 제2공장 증설, PT403 개발, SmartDepot 및 공동기술평가 등 관련 문의에 대한 답변 💊 Q5. SmartDepot™의 Ready-to-Use 제형 개발 및 제2공장 적용 계획은 어떻게 됩니까? 회사는 SmartDepot™ 기술을 적용한 제품의 경쟁력과 사용 편의성을 높이기 위해 다양한 제형 및 생산기술에 대한 연구개발을 지속하고 있습니다. 다만 특정 Ready-to-Use 제형의 구체적인 기술개발 단계와 제조공정, 제2공장에 설치될 개별 생산라인의 구성 및 사양 등은 현재 공개하고 있지 않습니다. 제2공장은 특정 단일 제품이나 제형을 위한 전용시설이 아니라 향후 SmartDepot™를 적용한 다양한 제품의 개발 및 상업생산과 복수의 사업기회에 유연하게 대응할 수 있는 생산

7 Aug 2026, 08:17 UTC84 viewsread 7 August 2026
Forwarded from @growthbioPhoto

🧬 펩트론 주요 문의(FAQ)에 대한 답변 (1) 제2공장 증설, PT403 개발, SmartDepot 및 공동기술평가 등 관련 문의에 대한 답변 💊 Q1. 제2공장은 현재도 9월 착공을 목표로 진행되고 있습니까? 네. 회사는 현재 9월 착공을 목표로 제2공장 증설을 추진하고 있으며, 해당 일정에 맞춰 설계 및 인허가를 비롯한 착공에 필요한 제반 절차를 진행하고 있습니다. 다만 대규모 GMP 생산시설 건설사업의 특성상 설계, 인허가 및 공사계획 등의 진행상황에 따라 세부 일정은 일부 조정될 수 있습니다. 착공을 비롯하여 주주 여러분께 안내드릴 수 있는 주요 일정이 구체화되는 경우 적절한 방법을 통해 안내드리겠습니다. 💊 Q2. 제2공장 규모를 확대하게 된 배경은 무엇이며, 특정 사업이나 파트너사를 전제로 한 것입니까? 회사는 S

7 Aug 2026, 08:09 UTC70 viewsread 7 August 2026
Forwarded from @alteogenIRPhoto

안녕하세요. 당사의 파트너제품 Keytruda Qlex의 지난 달(7월) Bloomberg WAC 데이터 아래와 같이 공유드립니다. ▶️ 7월 WAC: $201.6M (약 2,883억원, 직전 월 대비 약 20% 증가) ▶️ 키트루다 프랜차이즈(IV+SC) 중 점유율 약 10.6% (직전 월 8.9%) ▶️ 올해 1~7월 누적 매출액은 $688M(약 9,838억원) 이상으로 추정됨 (WAC은 wholesale acquisition cost로 MSD 실제 매출과 차이 있을 수 있습니다.)

7 Aug 2026, 06:35 UTC170 views0 reactionsread 7 August 2026

https://m.thebell.co.kr/m/newsview.asp?svccode=00&newskey=202608051015077440107185&page=1&sort=FREE_DTM&searchtxt=

7 Aug 2026, 06:31 UTC138 viewsread 7 August 2026
Forwarded from @bdragon0808

https://youtube.com/shorts/XsjdJtCSboo?si=2zFEc6gMJMd7I_u8

7 Aug 2026, 06:02 UTC137 viewsread 7 August 2026
Forwarded from @SmartnGrowth

알테오젠, 기술수출 마일스톤 덕 '고속 성장' - 2Q 매출 689억, 전년比 269.5%↑…영업익·순이익 흑자전환 https://dealsite.co.kr/articles/166787

7 Aug 2026, 04:50 UTC204 viewsread 7 August 2026

미국 바이오기업 모더나(Moderna)는 자사의 메신저 리보핵산(mRNA) 기반의 계절독감 백신인 ‘엠플루시바(mFLUSIVA, 개발코드명 mRNA-1010)’가 미국 식품의약국(FDA)으로부터 ‘50세 이상 성인’을 대상으로 승인받았다고 최근 밝혔습니다. 이번 승인은 FDA 산하 백신 및 관련 생물학적 제제 자문위원회(VRBPAC)가 50세 이상 성인을 대상으로 엠플루시바에 대한 사용을 ‘만장일치’로 권고한 데 따른 것입니다. 엠플루시바는 모더나가 전 세계에서 승인받은 5번째 제품이자, 미국에서 승인받은 4번째 제품이 됐습니다. 엠플루시바는 모더나의 mRNA 플랫폼 기반의 4가 계절독감 백신입니다. 기존 유정란 기반의 독감백신보다 실제 유행 바이러스와의 균주 일치도를 높일 수 있다는 점이 특징입니다. 회사는 이를 통해 ‘고령층’에서 상대

7 Aug 2026, 03:10 UTC191 viewsread 7 August 2026

미국 식품의약국(FDA)이 신약 후보물질 발굴부터 첫 인간 대상 임상시험(First-in-Human, FIH) 진입까지 걸리는 시간을 단축하기 위한 새로운 ‘임상시험계획(IND) 신속화 제도’ 도입을 추진합니다. 대학병원과 의료 네트워크, 임상시험수탁기관(CRO) 등 일정 요건을 갖춘 연구기관이 제약바이오 기업과 함께 ‘초기 임상 프로토콜’을 개발·검토하는 체계를 구축하는 것이 핵심입니다. FDA는 6일(현지시간) 이해관계자를 대상으로 ‘신속 IND 파일럿 프로그램(Expedited IND Pilot Program)’ 교육 웨비나를 열고, 프로그램의 추진 배경과 목적·운영 구조 등을 설명했습니다. 앞서 FDA는 지난 6월 24일 미국 정부 관보(Federal Register)를 통해 ‘파일럿 프로그램 도입안’을 공개하고 의견 수렴에 착수했으

Showing the 12 most recent of 20 posts we hold for @bioha1228. View and reaction counts are the latest single reading for each post, not a live figure, and a recent post is still accumulating both. A view count marked was rounded by Telegram before we ever saw it — t.me prints views in full below 1,000 and to three significant figures above, so ≈1,200,000 means somewhere between 1,150,000 and 1,249,999. Unmarked counts are exact. Text is reproduced from the public post preview and truncated for length.

Citation-graph rank

Citation-graph rank — 440,672 of 1,480,688entries in the measured graph. A weighted position computed from the forward and mention edges below — republished posts weigh more than named mentions — and recomputed periodically, over the whole graph. Published only as this ordinal position, never as a score: a position is a fact, and a score printed beside one channel’s name would read as a verdict this register does not make. The two counts beneath stay separate for the same reason mentions are never summed with forwards anywhere else on this page — a named-by count costs nothing to manufacture. The top 100 by this measure, or how it is computed.

Forward network

Built only from forwarded posts we have actually read, on both sides. Coverage is early and deliberately incomplete: a missing link means we have not read the post that would prove it, never that the relationship does not exist. Counts are distinct forwarded posts observed, so they only ever go up as we read more.

Mentions

Names

Channels on the register whose handles appear in this channel's posts.

A mention is a weaker signal than a forward and is counted separately for that reason — naming a channel is not republishing it, and a handle in a post body is easy to place deliberately. The post counts beside each row below are distinct posts in which the handle appeared, from posts we have read on both sides — the “Named by N registered channels” figure above is a different count, of distinct NAMING CHANNELS rather than posts, and is not the sum of the rows under it.

Cite this entry

A live page changes as we take new readings, so a citation should name the measurement it is based on, not just the URL. The line below cites the subscriber count as measured 14 August 2026 — this entry's latest reading, not the date you are reading this.

“(사)바이오헬스케어협회” (@bioha1228), 2,750 subscribers as measured 14 August 2026. Telegram Register, tgregister.com/channel/bioha1228.

Full measurement history, CC BY 4.0. Every reading this register holds for this entry, not just the latest one, as a dated, downloadable record: CSV · JSON. Free to use with attribution to tgregister.com. Each file carries its own generation timestamp, which is the figure to cite for exactly when the data was retrieved.